Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1Phase 1 1

Status

Unknown 1Recruiting 1Completed 1

Sponsor Class

OTHER 137INDUSTRY 33NIH 25NETWORK 4OTHER_GOV 3FED 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1Ovarian Neoplasms 1Lung Neoplasms 1Fallopian Tube Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Capecitabine 28apatinib 26Oxaliplatin 24Cisplatin 24tislelizumab 23Gemcitabine 23Irinotecan 19Paclitaxel 18Carboplatin 18Docetaxel 15Bevacizumab 15Fluorouracil 14Drug Therapy 13Cyclophosphamide 11pembrolizumab 10camrelizumab 10Vinorelbine 9Radiation 9S 1 (combination) 8Leucovorin 8Cetuximab 8toripalimab 7sintilimab 7Rituximab 7Erlotinib Hydrochloride 7pyrotinib 6Gefitinib 6Albumin-Bound Paclitaxel 6fludarabine 5anlotinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × OTHER_GOV × olaparib × Clear all
NCT05200260 2025-02-10

Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer

Shanghai Gynecologic Oncology Group

Phase 2 Recruiting
220 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02511223 2023-04-19

10

Sheba Medical Center

Phase 2 Completed
24 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT01788332 2018-10-26

PIN

Velindre NHS Trust

Phase 2 Unknown
70 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡